Trial Profile

Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doravirine (Primary) ; Emtricitabine/tenofovir alafenamide (Primary)
Indications HIV-1 infections
Focus Pharmacodynamics; Pharmacokinetics; Registrational
Acronyms DORACeNeS

Most Recent Events

27 Apr 2022 The primary endpoints Unbound Doravirine Concentrations in CSF, Doravirine Concentrations in Blood Plasma, and Unbound Doravirine Concentration CSF/Plasma Ratio were added, according to ClinicalTrials.gov record.
27 Apr 2022 Status changed from recruiting to completed.
12 Sep 2021 Status has been changed to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com